Virtual Library

Start Your Search

Gerald Sng



Author of

  • +

    P1.16 - Surgery (ID 702)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Surgery
    • Presentations: 1
    • +

      P1.16-013 - Video-Assisted Thoracoscopic Surgery (VATS) versus Thoracotomy in Locally-Advanced Lung Cancers – a Meta-Analysis (ID 9231)

      09:30 - 09:30  |  Presenting Author(s): Gerald Sng

      • Abstract
      • Slides

      Background:
      Video-assisted thoracoscopic surgery (VATS) has been established as the preferred approach for surgical resection of early-stage non-small cell lung cancers. It is shown to have improved oncological outcomes with lower perioperative complication rates when compared with conventional open lobectomy. However, there is a paucity of high-level evidence supporting its use in locally-advanced lung cancers. Moreover, published results have shown contrasting outcomes. We conducted a meta-analysis to compare oncological outcomes as well as perioperative complications for VATS versus conventional thoracotomy in this population.

      Method:
      Electronic databases (PubMed MEDLINE, EMBASE and Web of Science) were searched for studies evaluating VATS versus conventional thoracotomy for the resection of locally-advanced lung cancers. Individual outcome data was pooled to investigate the summary effect.

      Result:
      A total of 5 studies comparing the two approaches were identified. Of these, only 3 studies reported long-term survival data appropriately and were analysed separately. There was no difference in 3-year overall survival (HR 0.67, 95% CI 0.29-1.53) or 3-year disease-free survival (HR 1.09, 95% CI 0.77-1.55) when comparing VATS against open thoracotomy. However, VATS was associated with a shorter length of stay (2.02 days, 95% CI 0.65-3.39 days). There was no difference in blood loss between the two approaches.

      Conclusion:
      Oncological outcomes of VATS resection appear to be at least equivalent to conventional thoracotomy in locally-advanced lung cancers. Length of stay is shorter for VATS, which has been shown to correlate with better cost-effectiveness. Ideally, randomised controlled trials should be designed to confirm and further investigate these conclusions.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.